Jada Pinkett Smith on Menopause Medication: What She Actually Said and What the Science Shows

What Jada Pinkett Smith Has Actually Said About Menopause

Jada Pinkett Smith brought menopause into mainstream celebrity conversation in a way that few public figures have done openly. On Red Table Talk, the Facebook Watch series she co-hosted with her mother Adrienne Banfield-Norris and daughter Willow Smith, she addressed both her menopause experience and her diagnosis of alopecia areata with unusual candor for a Hollywood figure.

In a 2018 Red Table Talk episode focused on hair loss, Pinkett Smith disclosed her alopecia diagnosis and described the emotional weight of watching her hair fall out in clumps in the shower. She described the experience as frightening and shared that it had pushed her toward a short, then shaved, hairstyle as a way to reclaim control. The alopecia episode predated her public menopause discussions but is clinically relevant because alopecia areata and androgenetic alopecia both have documented associations with hormonal shifts during perimenopause and menopause.

In later conversations on the show, Pinkett Smith and her mother discussed the menopause experience across generations, including hot flashes, sleep disruption, and mood changes. Adrienne Banfield-Norris spoke more explicitly about her own experience with menopause symptoms, and the intergenerational framing gave viewers a rare look at how the same biological transition can differ across family lines.

What She Has Not Said

Pinkett Smith has not, in any on-record interview, podcast appearance, or verified social media post available at the time of publication, named a specific menopause medication, hormone therapy product, or supplement she uses or has used. Any claim circulating online that she takes a specific drug or supplement is either unverified or fabricated. This article will not repeat those claims as fact.

Where inference appears below, it is labeled clearly as inference or as a clinical discussion of what is typically offered to women at her life stage.

Why Her Openness Matters Clinically

The average woman waits more than three years before speaking to a clinician about menopause symptoms, often because she does not recognize them as menopause-related or fears being dismissed. Celebrity disclosure does not replace medical care, but it does reduce the silence around a transition that affects every woman. That reduction in silence has measurable downstream effects: women who feel informed are more likely to seek evaluation and to discuss treatment options with their providers.

The Menopause and Perimenopause Transition: What Is Actually Happening

Menopause is defined as 12 consecutive months without a menstrual period, and the median age in the United States is 51, though the normal range spans 45 to 55. Perimenopause, the transition leading up to that point, can begin 4 to 8 years earlier and is often the phase where symptoms are most new because estrogen levels fluctuate erratically rather than declining steadily.

Vasomotor symptoms, meaning hot flashes and night sweats, affect approximately 75% of women during the menopause transition. Sleep disruption, mood changes, cognitive fogginess, joint aches, and changes in sexual function are also common. Hair thinning is reported by a significant proportion of women in this life stage, driven by the relative rise in androgens as estrogen falls.

The Hormonal Shift and Female Hair Loss

The connection between Pinkett Smith's alopecia and her menopause timeline is worth understanding clearly. There are two distinct hair loss patterns that become more common in midlife women.

Androgenetic alopecia (female pattern hair loss) is driven by the same androgens that become relatively more prominent as estrogen declines in perimenopause. It presents as diffuse thinning at the crown and widening of the part line.

Alopecia areata is an autoimmune condition, and it is the type Pinkett Smith has publicly identified as her diagnosis. It presents as patchy, sudden hair loss and is not caused by androgens. The relationship between alopecia areata and hormonal transitions is less direct, but immune dysregulation during perimenopause has been proposed as a contributing factor in autoimmune flares. The two conditions can coexist, which adds complexity to diagnosis and treatment.

Life Stage Differences in Symptom Presentation

Symptoms vary substantially depending on where a woman is in the transition:

• Reproductive years (under 40): Premature ovarian insufficiency (POI) affects roughly 1% of women and causes menopause-like symptoms earlier. Treatment approach differs from natural menopause.
• Perimenopause (typically 45-52): Cycles become irregular; estrogen fluctuates widely. This is often when vasomotor symptoms are most severe and when hormonal contraception may mask cycle irregularity.
• Postmenopause (12+ months after final period): Estrogen stabilizes at a low level. Genitourinary syndrome of menopause (GSM), bone loss, and cardiovascular risk become increasingly relevant.

What Clinicians Actually Offer Women at This Life Stage

Because Pinkett Smith has not publicly named medications, the clinical discussion below covers what a well-informed clinician would typically consider for a woman presenting with menopausal symptoms, alopecia areata, and the other concerns she has described on Red Table Talk.

Hormone Therapy

The Menopause Society (formerly NAMS) 2023 Position Statement states that hormone therapy is the most effective treatment for vasomotor symptoms and is appropriate for healthy women under age 60 or within 10 years of menopause onset, where the benefits generally outweigh the risks. This is the most important evidence-based statement in this space, and it reflects a significant shift from the fearful post-WHI (Women's Health Initiative) era.

The WHI, published in 2002 in JAMA, initially caused widespread abandonment of hormone therapy due to reported increased risks of breast cancer and cardiovascular events. Later reanalysis, particularly data from the WHI Memory Study and subsequent subgroup analyses, showed that the risks were concentrated in older women who started therapy more than 10 years after menopause, not in younger women starting during the transition. This "timing hypothesis" or "window of opportunity" is now central to how clinicians counsel women.

Types of hormone therapy a clinician might discuss:

• Systemic estrogen (oral, transdermal patch, gel, or spray): The backbone of symptom management for hot flashes, sleep, and mood.
• Progesterone or progestogen: Required in women with a uterus to protect the uterine lining from unopposed estrogen.
• Testosterone: Not FDA-approved for women in the United States at the time of publication, but used off-label for hypoactive sexual desire disorder (HSDD) and sometimes energy; evidence is growing.
• Local vaginal estrogen: Low-dose, minimal systemic absorption; recommended for GSM symptoms regardless of age or cardiovascular risk.

Non-Hormonal Prescription Options

For women who cannot or choose not to use hormone therapy, several evidence-based non-hormonal options exist:

• Fezolinetant (Veozah): The first FDA-approved non-hormonal treatment specifically for vasomotor symptoms, approved in May 2023. It works by blocking the neurokinin B pathway in the hypothalamus.
• SSRIs and SNRIs: Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for vasomotor symptoms; others like venlafaxine and escitalopram are used off-label with reasonable evidence.
• Gabapentin: Modestly effective for hot flashes and sleep; not a first-line agent.

Treatments for Alopecia Areata Specifically

Alopecia areata treatment is separate from menopause management. Options include:

• Intralesional corticosteroid injections: First-line for patchy disease.
• Topical minoxidil: Supports regrowth in some cases.
• JAK inhibitors (baricitinib, ritlecitinib): The newest class; ritlecitinib was FDA-approved in June 2023 specifically for alopecia areata in adults and adolescents 12 and older.
• Topical calcineurin inhibitors and contact immunotherapy: Specialist-level options.

Whether hormone therapy improves alopecia areata is not established in controlled trials. Anecdotally, some women report hair changes with hormonal shifts, but this should not be the primary driver of the hormone therapy decision.

Pregnancy, Lactation, and Contraception During Perimenopause

This section is required for any article touching medications used during hormonal transitions, because many women in perimenopause incorrectly assume they cannot conceive.

Can You Still Get Pregnant in Perimenopause?

Yes. Fertility declines sharply in the late 40s, but ovulation can still occur unpredictably during perimenopause. Unintended pregnancy rates in women aged 40-44 are not negligible, and the consequences of an unintended pregnancy in this age group carry higher obstetric risks including chromosomal abnormalities and pregnancy complications.

ACOG recommends that women continue contraception until 12 consecutive months after their final menstrual period if they are under 50, and for 24 months if they experienced menopause before age 50.

Hormone Therapy and Pregnancy

Systemic hormone therapy at menopausal doses is not a contraceptive. Women who are perimenopausal and sexually active with a risk of pregnancy need reliable contraception in addition to any hormone therapy they are using. Low-dose hormonal contraceptives (the pill, patch, ring, IUD with levonorgestrel, or implant) can serve a dual purpose: contraception and symptom management.

Systemic estrogen at menopausal doses has not been studied in pregnancy because it is not indicated in pregnant women. If a woman on hormone therapy discovers she is pregnant, she should stop the medication and contact her clinician immediately.

Lactation

Menopausal hormone therapy is not used during breastfeeding. By the time a woman is entering menopause, breastfeeding is not typically a consideration. However, for women with premature ovarian insufficiency (POI) in their 30s who may be lactating after a recent birth, hormone therapy decisions require specialist guidance because data in this specific situation is extremely limited. This is an acknowledged evidence gap.

Fezolinetant (Veozah) has no human lactation data. The FDA prescribing information advises against use during breastfeeding. SSRIs used for vasomotor symptoms have varying lactation transfer profiles; paroxetine has relatively low transfer and is used in postpartum depression, but its use for menopause symptoms in a lactating woman is a specialist conversation.

How This Connects to PCOS, Thyroid, and Other Female Conditions

Menopause does not occur in isolation, and for many women it arrives on top of pre-existing hormonal conditions.

PCOS: Women with polycystic ovary syndrome often have a later natural menopause and different hormonal profiles at baseline. The elevated androgen environment of PCOS may alter how hair loss presents during the transition. Metformin, often used in PCOS management, is not a menopause treatment.

Thyroid disease: Hypothyroidism and hyperthyroidism are more common in women than men, and thyroid dysfunction can mimic or worsen menopause symptoms including fatigue, mood changes, hair loss, and irregular cycles. Before attributing symptoms solely to menopause, thyroid function testing (TSH, free T4) is standard clinical practice. Postpartum thyroiditis affects approximately 5-10% of women after delivery and may precede autoimmune thyroid patterns that appear again during menopause.

Autoimmune conditions: Pinkett Smith's alopecia areata is an autoimmune condition. Women carry a disproportionate burden of autoimmune disease, accounting for roughly 80% of autoimmune diagnoses in the United States. The hormonal changes of perimenopause can influence immune regulation, though the direction and magnitude of this effect vary by condition.

The Evidence Gap: What We Actually Do Not Know

Most large menopause trials have enrolled postmenopausal women who are on average 3 to 10 years past their final period. The perimenopausal window, which is often when women seek care and when symptoms are most new, is substantially understudied. The WHI enrolled women with a mean age of 63, far older than the typical woman first presenting with perimenopausal symptoms.

For hair loss specifically, there are no randomized controlled trials examining hormone therapy as a treatment for alopecia areata in perimenopausal women. The dermatology and gynecology specialties rarely collaborate on this question in trial design.

For celebrity disclosures specifically, there is an additional layer of uncertainty: public figures often receive boutique or off-label care that reflects access and resources rather than standard evidence-based practice. What works for one individual in a specific clinical context is not generalizable. When a celebrity says they "take something" without specifying dose, formulation, duration, monitoring, or clinical indication, the information has almost no clinical utility for another woman making her own health decision.

This is why the WomanRx editorial standard distinguishes between "what was said," "what can be inferred," and "what the evidence supports" as three separate categories. In Pinkett Smith's case: she said she has menopause and alopecia. What she takes is unconfirmed. What the evidence supports for women in her situation is described above.

Who This Information Is For and Who Should Seek Specialist Care

This information is most relevant if you:

• Are between 40 and 55 and noticing irregular periods, hot flashes, night sweats, or sleep disruption.
• Have a personal or family history of alopecia areata or androgenetic hair loss.
• Have PCOS or an autoimmune condition and are approaching the menopause transition.
• Are looking for context around celebrity menopause discussions and want evidence-based framing.

You should seek specialist evaluation rather than self-treating if:

• You experience menopause symptoms before age 40 (this may indicate premature ovarian insufficiency and requires different management, including bone density monitoring and cardiovascular risk assessment).
• Your hair loss is sudden, patchy, or accompanied by scalp inflammation.
• You have a history of breast cancer, stroke, blood clots, or liver disease, as these affect hormone therapy eligibility.
• You are perimenopausal and sexually active without reliable contraception.

A NAMS-certified menopause practitioner, reproductive endocrinologist, or OB-GYN with a menopause focus is the appropriate clinician for personalized hormone therapy decisions. Dermatologists with a hair loss specialty handle alopecia areata evaluation. The Menopause Society's provider locator can help you find a certified practitioner in your area.

A Note on Journalistic and Clinical Standards

WomanRx treats celebrity health disclosures as a starting point for clinical education, not as medical evidence. Jada Pinkett Smith's openness about menopause and alopecia has contributed to reducing the cultural silence around these conditions. That contribution is real and worth acknowledging.

What it does not do is tell us whether hormone therapy, a JAK inhibitor, a dietary change, or any other intervention is right for you. Your symptom burden, medical history, reproductive plans, and personal values all factor into that conversation. The Menopause Society 2023 Position Statement is the current gold standard for that clinical decision framework in the United States.

If you are in the perimenopausal window and have not yet had a structured conversation with a clinician about your options, schedule that appointment. Bring a symptom log covering the past 2 to 3 months, your menstrual calendar, and any questions this article raised.